Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021)
Transcode Therapeutics' (RNAZ) quarterly Convertible Debt came in at $2.1 million in Q2 2021, up 1.88% quarter-over-quarter from $2.1 million in Q4 2020.
Powered by 
Analysis
Transcode Therapeutics (RNAZ) Convertible Debt (2020 - 2021) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Convertible Debt for 2 consecutive years, with $2.1 million the latest figure, recorded in Q2 2021.
- For the quarter ending Q2 2021, Convertible Debt changed N/A year-over-year to $2.1 million; the trailing twelve-month figure through Jun 2021 stood at $2.1 million (changed N/A YoY), and the FY2020 full-year result was $2.1 million, changed N/A from the prior year.
- Convertible Debt advanced to $2.1 million in Q2 2021 per RNAZ's latest filing, from $2.1 million in the prior quarter.
- Across five years, Convertible Debt topped out at $2.1 million in Q2 2021 and bottomed at $2.1 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn |
| 10 | Transcode Therapeutics | 1.68 Mn | 1.68 Mn | - |